Thymosin alpha 1 reduced mortality in severe COVID-19 patients from 30% to 11% by reversing lymphocytopenia and T cell exhaustion through enhanced thymic output.
30% → 11.1% mortalityTα1 treatment nearly tripled survival in severe COVID-19 patients (P=.044)
What the researchers found
Tα1 reduced severe COVID-19 mortality from 30% to 11.1% (P=.044), restored CD4+ and CD8+ T cell counts, and reversed T cell exhaustion markers (PD-1, Tim-3).
Why it matters
Severe COVID-19 kills partly through immune exhaustion. A peptide that restores T cell function rather than suppressing immunity addresses the root cause — and may apply to other viral infections.
The numbers in context
Mortality 11.11% vs 30.00% (p=0.044); benefit threshold CD8+ <400/uL or CD4+ <650/uL; reduced PD-1 and Tim-3 on CD8+ T cells
How the study worked
Retrospective review of 76 severe COVID-19 patients from 2 Wuhan hospitals (Dec 2019-Mar 2020). Tα1-treated vs untreated; measured: mortality, T cell counts, TRECs (thymic output), PD-1 and Tim-3 expression on CD8+ T cells by flow cytometry.
Who was studied
76 severe COVID-19 patients at 2 hospitals in Wuhan, China (December 2019 to March 2020)
What this study cannot tell us
Retrospective non-randomized study — potential selection bias; small sample (76); single-center data from early pandemic (Dec 2019-Mar 2020); no standardized treatment protocol.
How to read the evidence
Moderate-high — significant mortality reduction with mechanistic immunological data, but limited by retrospective non-randomized design.
When this study was published
Published in 2020 from early pandemic data; subsequent COVID-19 treatments have evolved significantly.
The bigger picture
Thymosin alpha 1 has been used for decades in viral hepatitis. Its success in COVID-19 reinforces the concept that immune restoration — not just antiviral drugs — can save lives in severe infections.
Questions still open
- Would a randomized controlled trial confirm the mortality benefit?
- Can Tα1 be used prophylactically for high-risk patients before severe disease develops?
- Does Tα1 benefit patients with other viral infections that cause lymphocytopenia?
Common questions
What is thymosin alpha 1?
Who benefited most?
Read the original research
Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(16), 2150-2157
Citation
Liu, Yueping; Pan, Yue; Hu, Zhenhong; Wu, Ming; Wang, Chenhui; Feng, Zeqing; Mao, Congzheng; Tan, Yingjun; Liu, Ying; Chen, Li; Li, Min; Wang, Gang; Yuan, Zilin; Diao, Bo; Wu, Yuzhang; Chen, Yongwen. (2020). Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(16), 2150-2157. https://doi.org/10.1093/cid/ciaa630